JBIO Stock Summary and Trading Ideas (Jade Biosciences | NASDAQ:JBIO)

Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.

Jade Biosciences trades on the NASDAQ stock market under the symbol JBIO.

As of February 20, 2026, JBIO stock price declined to $14.27 with 249,650 million shares trading.

JBIO has a beta of 0.01, meaning it tends to be less sensitive to market movements. JBIO has a correlation of 0.00 to the broad based SPY ETF.

JBIO has a market cap of $703.72 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that JBIO belongs to (by Net Assets): VTI, IWM, IWN, VXF, VTWO.

JBIO support price is $13.64 and resistance is $15.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JBIO shares will trade within this expected range on the day.